Comparison of Superior Hypogastric Plexus Block and Peritoneal Bupivacaine in Pain Management

CompletedOBSERVATIONAL
Enrollment

94

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

February 20, 2025

Conditions
Superior Hypogastric Plexus BlockIntraperitoneal Bupivacaine
Interventions
DRUG

Bupivacain

The superior hypogastric plexus block (SHPB) was performed following uterine removal and closure of the vaginal cuff, but prior to trocar removal from the abdominal cavity. The promontory was identified under laparoscopic visualization. The posterior peritoneum overlying the promontory was gently grasped and elevated with an instrument to create a peritoneal tent. A needle was then inserted at the apex of the tent and advanced approximately 1 cm. At this point, a subperitoneal space was further expanded using a surgical instrument, and 30 ml of 0.25% bupivacaine was injected into the area

DRUG

Dexketoprofen (KETAVEL 50 mg/2 ml)

In cases where the VAS score exceeded 3 in the postoperative period, it was deemed that the patient's analgesia was insufficient, prompting the intravenous administration of 50 mg of dexketoprofen sodium.

DRUG

Intraperitoneal Bupivacaine spray

The peritoneal cavity and abdominal wall were treated with 30 milliliters of 0.25% bupivacaine, with a focus on areas involving the peritoneum in the lower abdominal region.

Trial Locations (1)

Unknown

Mardin Artuklu University, Mardin

All Listed Sponsors
lead

Enes Celik

OTHER

NCT06954896 - Comparison of Superior Hypogastric Plexus Block and Peritoneal Bupivacaine in Pain Management | Biotech Hunter | Biotech Hunter